PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Files An 8-K Other Events

ME Staff 8-k
-
0

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Files An 8-K Other Events

Item 8.01 Other Events.

On May 27, 2017, PetLife Pharmaceuticals, Inc. (PetLife) released
a press release titled PetLife Management Comments on Recent
Market Activity, which stated certain current evaluations by
PetLife management on the PetLifes press releases and other
activity (Press Release 5/27/17. see Exhibit 99.1).

As stated within Press Release 5/27/17, PetLife has issued
several other press releases since August 25, 2016. After Press
Release 5/27/17, PetLife issued a press release at 6AM EDT on May
30, 2017, titled PetLife Files for Patent for the Treatment of
Cancer for Pets (see Exhibit 99.2). The press releases from May
27, 2017 back to August 25, 2016, as reflected in descending
order, are as stated below:

May 26, 2017 PetLife Explores New Scorpion Venom-Based Therapies for
Growing Product Line 		Press Release
May 23, 2017 PetLife Closes Acquisition of Assets for Dr. Geoff’s Real
Food for Pets 		Press Release
May 16, 2017 PetLife Pharmaceuticals Engages Carter, Terry Company for
Financing of FDA Application 		Press Release
Apr 18, 2017 PetLife Finalizes Negotiations for Dr. Geoffs Real Food
for Pets 		Press Release
Apr 12, 2017 PetLife: Holistic Pet Health is Next Big Trend in
Veterinary Medicine 		Press Release
Mar 24, 2017 PetLife: Millennial Pet Owners Leading Charge in Rapid
Growth of Holistic Pet Care 		Press Release
Mar 21, 2017 PetLife Supersedes Expectations for the Acquisition of Dr.
Geoffs Real Food for Pets 		Press Release
Mar 7, 2017 PetLife Pharmaceuticals Provides an Eye-Opening View on a
Recession Resistive Industry 		Press Release
Feb 28, 2017 PetLife Pharmaceuticals Signs Letter of Intent to Acquire
Healthy Life Pets Brand 		Press Release
Feb 21, 2017 PetLife Pharmaceutical Taps National Public Relations Firm
to Help Bring to Market Cancer Treatment Originally Developed
by Cuba 		Press Release
Feb 9, 2017 World Renowned Veterinary Nutritionist Dr. R. Geoffrey
Broderick Continues Groundbreaking Efforts to Help Animals by
Joining PetLife Pharmaceuticals, Inc. as the Chairman of
Product Development and Advisory Board 		Press Release
Feb 3, 2017 PetLife Pharmaceuticals Announces Son of World Famous
Veterinarian Pet Industry Innovator, Geoffrey Broderick, to
Join the Company as the New President 		Press Release
Jan 10, 2017 PetLife Pharmaceuticals reports the First of Three
Preclinical Studies in their pre-INAD Process for Vitalzul.
Blue Scorpion Venom Toxicity Study Results Show No Adverse
Reactions across Multiple Dosing Levels. 		Press Release
Dec 7, 2016 Correction: PetLife Pharmaceuticals Enters Negotiations
with Key Founders of InnoVision Therapeutics to Discuss
Expansion of its Core Product Line 		Press Release
Dec 7, 2016 PetLife Pharmaceuticals Enters Negotiations with Key
Founders of InnoVision Therapeutics to Discuss Expansion of
its Core Product Line 		Press Release
Dec 6, 2016 PetLife Pharmaceuticals CEO Dr. Salvagno Provides White
Paper on Venenotherapy While Preparing for FDA Submission 		Press Release
Dec 1, 2016 PetLife Pharmaceuticals Updates Shareholders on the
Company Progress with Vitalzul Studies and Additional Product
Offerings 		Press Release
Nov 15, 2016 PetLife Pharmaceuticals Notes Recent Cuban Research
Providing Profound Evidence of Caribbean Blue Scorpion
Venom’s Ability to Eradicate Cancer Cells as Continued
Support for PetLife’s pre- INAD Studies of Vitalzul 		Press Release
Oct 27, 2016 PetLife Pharmaceuticals and Lumleian, LLC Announce
Partnership to Advance Development and Commercialization of
Promising Veterinary Health Pipeline 		Press Release
Oct 24, 2016 PetLife Pharmaceuticals Announces the Addition of a
Seasoned Marketing Specialist and Investor, Mrs. Vyvyan
Campbell, to the Board of Directors 		Press Release
Oct 20, 2016 PetLife Pharmaceuticals Announces the Addition of Dr.
Simon Wood PhD as the Companys new Scientific Officer with
plans to expand its Current Portfolio of Veterinarian Drugs
and Nutraceuticals 		Press Release
Oct 17, 2016 PetLife Pharmaceuticals is Pleased to Announce the
Completion of the New Company Website 		Press Release
Oct 13, 2016 PetLife Pharmaceuticals Expands Cell Line Study with
InnoVision in Preparation for FDA/CVM Registration
Submission 		Press Release
Oct 10, 2016 PetLife Pharmaceuticals is Pleased to Showcase its New
Vitalzul Information Video along with a Corporate Update 		Press Release
Sep 7, 2016 PetLife Pharmaceuticals Announces pre-INAD
(Investigational New Animal Drug) Cell Lines Study of
Vitalzul has Begun 		Press Release
Sep 1, 2016 PetLife Pharmaceuticals Sees Vitalzul as a Major Component
in the Treatment of Cancer in Pets; Releases Vitalzul
Information and Testimonial Video 		Press Release
Aug 25, 2016 PetLife Pharmaceuticals Hires InnoVision Therapeutics in
Preparation of Vitalzul FDA Submission 		Press Release

As reflected in the 27 press releases issued by PetLife since
August 25, 2016 through May 26. 2017, which does not include
Press Release 5/27/17, over the 9-month period, PetLife has
averaged 3 press releases per month, with an actual breakdown, by
month, as follows: May 2017, 3; April 2017, 2; March 2017, 3;
February 2017, 4; January 2017, 1; December 2016, 4; November
2016, 1; October 2016, 6; September 2016, 2; and August 2016, 1.
The 27 press releases are seen in Exhibits 99.3 through 99.29.

The press releases reflect the growth of PetLife, specifically in
its flagship product, Vitalzul. The development of Vitalzul, as
reflected over time shows the path to application to the United
States Food and Drug Administration (FDA) and noted intellectual
properties.

PetLife has, from time-to-time, contracted with third-party firms
that specialize in investor and public relations. PetLife has
used the following firms, as reflected below, during the stated
periods.

Gregory FCA February 20, 2017 to April 20, 2017
Invicto Group July 8, 2016 to October 8, 2016
Worldwide Holdings dba Invictus Resources September 1, 2016 to November 30, 2016

PetLife, since January 1, 2016, has not had any conversions from
debt instruments into securities of PetLife.

Item 9.01 Financial Statements and Exhibits.

The exhibits listed in the following Exhibit Index are filed as
part of this report:

Exhibit No. Description
99.1 Press Release titled PetLife Management Comments on Recent
Market Activity as released on May 28, 2017
99.2 Press Release titled PetLife Files for Patent for the
Treatment of Cancer for Pets as released on May 30, 2017
99.3 Press Release titled PetLife Explores New Scorpion
Venom-Based Therapies for Growing Product Line as released on
May 26, 2017
99.4 Press Release titled PetLife Closes Acquisition of Assets for
Dr. Geoffs Real Food for Pets as released on May 23, 2017
99.5 Press Release titled PetLife Pharmaceuticals Engages Carter,
Terry Company for Financing of FDA Application as released on
May 16, 2017
99.6 Press Release titled PetLife Finalizes Negotiations for Dr.
Geoffs Real Food for Pets as released on April 18, 2017
99.7 Press Release titled PetLife: Holistic Pet Health is Next Big
Trend in Veterinary Medicine as released on April 12, 2017
99.8 Press Release titled PetLife: Millennial Pet Owners Leading
Charge in Rapid Growth of Holistic Pet Care as released on
March 24, 2017
99.9 Press Release titled PetLife Supersedes Expectations for the
Acquisition of Dr. Geoffs Real Food for Pets as released on
March 21, 2017
99.10 Press Release titled PetLife Pharmaceuticals Provides an
Eye-Opening View on a Recession Resistive Industry as
released on March 7, 2017
99.11 Press Release titled PetLife Pharmaceuticals Signs Letter of
Intent to Acquire Healthy Life Pets Brand as released on
February 28, 2017
99.12 Press Release titled PetLife Pharmaceutical Taps National
Public Relations Firm to Help Bring to Market Cancer
Treatment Originally Developed by Cuba as released on
February 21, 2017
99.13 Press Release titled World Renowned Veterinary Nutritionist
Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to
Help Animals by Joining PetLife Pharmaceuticals, Inc. as the
Chairman of Product Development and Advisory Board as
released on February 9, 2017
99.14 Press Release titled PetLife Pharmaceuticals Announces Son of
World Famous Veterinarian Pet Industry Innovator, Geoffrey
Broderick, to Join the Company as the New President as
released on February 3, 2017
99.15 Press Release titled PetLife Pharmaceuticals reports the
First of Three Preclinical Studies in their pre-INAD Process
for Vitalzul.Blue Scorpion Venom Toxicity Study Results Show
No Adverse Reactions across Multiple Dosing Levels as
released on January 10, 2017
99.16 Press Release titled Correction: PetLife Pharmaceuticals
Enters Negotiations with Key Founders of InnoVision
Therapeutics to Discuss Expansion of its Core Product Line as
released on December 7, 2016
99.17 Press Release titled PetLife Pharmaceuticals Enters
Negotiations with Key Founders of InnoVision Therapeutics to
Discuss Expansion of its Core Product Line as released on
December 7, 2016
99.18 Press Release titled PetLife Pharmaceuticals CEO Dr. Salvagno
Provides White Paper on Venenotherapy While Preparing for FDA
Submission as released on December 6, 2016
99.19 Press Release titled PetLife Pharmaceuticals Updates
Shareholders on the Company Progress with Vitalzul Studies
and Additional Product Offerings as released on December 1,
2016
99.20 Press Release titled PetLife Pharmaceuticals Notes Recent
Cuban Research Providing Profound Evidence of Caribbean Blue
Scorpion Venoms Ability to Eradicate Cancer Cells as
Continued Support for PetLifes pre-INAD Studies of Vitalzul
as released on November 15, 2016
99.21 Press Release titled PetLife Pharmaceuticals and Lumleian,
LLC Announce Partnership to Advance Development and
Commercialization of Promising Veterinary Health Pipeline as
released on October 27, 2016
99.22 Press Release titled PetLife Pharmaceuticals Announces the
Addition of a Seasoned Marketing Specialist and Investor,
Mrs. Vyvyan Campbell, to the Board of Directors as released
on October 24, 2016
99.23 Press Release titled PetLife Pharmaceuticals Announces the
Addition of Dr. Simon Wood PhD as the Companys new Scientific
Officer with plans to expand its Current Portfolio of
Veterinarian Drugs and Nutraceuticals as released on October
20, 2016
99.24 Press Release titled PetLife Pharmaceuticals is Pleased to
Announce the Completion of the New Company Website as
released on October 17, 2016
99.25 Press Release titled PetLife Pharmaceuticals Expands Cell
Line Study with InnoVision in Preparation for FDA/CVM
Registration Submission as released on October 13, 2016
99.26 Press Release titled PetLife Pharmaceuticals is Pleased to
Showcase its New Vitalzul Information Video along with a
Corporate Update as released on October 10, 2016
99.27 Press Release titled PetLife Pharmaceuticals Announces
pre-INAD (Investigational New Animal Drug) Cell Lines Study
of Vitalzul has Begun as released on September 7, 2016
99.28 Press Release titled PetLife Pharmaceuticals Sees Vitalzul as
a Major Component in the Treatment of Cancer in Pets;
Releases Vitalzul Information and Testimonial Video as
released September 1, 2016
99.29 Press Release titled PetLife Pharmaceuticals Hires InnoVision
Therapeutics in Preparation of Vitalzul FDA Submission as
released on August 25, 2016


About PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF)

PetLife Pharmaceuticals, Inc., formerly Clear TV Ventures, Inc., is engaged in the development and launching of a high potency (HP) veterinary cancer medications and nutraceuticals, based on the formula Escozine. The Company’s formula, Escozine (for humans) is sold as either a nutraceutical or prescription drug in approximately 40 countries, including the United States. It has rights to formulate, package and market a product line, Escozine for Pets, for livestock suffering from cancer. Escozine for Pets is a natural product containing serum derived from the Caribbean Blue Scorpion and polarized using the Company’s polarization technology. It intends to target various veterinary cancers, including Lymphoma, Osteosarcoma, Mast Cell Tumor, Melanoma, Squamous Cell Carcinoma, Mammary Carcinoma, Transitional Cell Carcinoma and Soft Tissue Sarcoma. It has designed three products for differentiated intake protocols for home and veterinary usage: Oral/Rectal, Patch and Injectable.

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Recent Trading Information

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) closed its last trading session down -0.146 at 0.360 with 197,241 shares trading hands.